Social media defined as "a conversation supported by online tools," is transforming the way people communicate across the globe. Basically, social media consists of online applications that allow users to generate content, connect with others, and engage in conversation. Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments. It includes educational banks, public health information dissemination, and online data-platform sharing. Patients use healthcare social media for peer support and empowerment through patient-centered websites.
Web 2.0 is a philosophy associated with online applications that facilitates interactive information sharing, collaboration, while being user-centered. Web 2.0 was adopted by healthcare participants to utilize the core concepts of openness, social networking, participation, collaboration, and apomediation. Apomediation refers to cutting out any middlemen or "gatekeepers" when accessing Internet information and going directly to the information, which is vetted by experts.
"One major concern of healthcare professionals regarding the use of social media in healthcare is that, by nature, it is open and the information is not ‘controllable,’” according to Jeff Cain, EdD, MS, director of education technology at the University of Kentucky College of Pharmacy, Lexington, Ky., who spoke on this topic at the 22nd annual meeting of the Academy of Managed Care Pharmacy in San Diego.
"Many healthcare professionals also use micro-blogging applications such as Twitter to disseminate and receive health-related information and research. By following other healthcare Twitterers, one can quickly be introduced to new publications, stories, and online articles of interest that she or he may not have discovered without extensive searching," said Dr Cain.
Examples of healthcare community sharing sites are PatientsLikeMe, HelloHealth, and Google Health. PatientsLikeMe is a site for patients with similar disease states. Currently there are more than 60,000 users for 19 conditions. Patients communicate about treatments, side effects, and other topics. Patient information is de-identified and aggregated, and can be purchased by pharmaceutical companies and health plans, to be used for research and marketing purposes.
“From the patient perspective, social media has permitted the unprecedented ability for users to socially connect with others who suffer from the same affliction or disease state,” according to Dr Cain. “For those with rare diseases, social networking capabilities of some of the patient community sites allow patients to locate, communicate with, encourage, and support others with similar problems.”
Social networking helpful for patients, but may need to be vetted
Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments.
Social media defined as "a conversation supported by online tools," is transforming the way people communicate across the globe. Basically, social media consists of online applications that allow users to generate content, connect with others, and engage in conversation. Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments. It includes educational banks, public health information dissemination, and online data-platform sharing. Patients use healthcare social media for peer support and empowerment through patient-centered websites.
Web 2.0 is a philosophy associated with online applications that facilitates interactive information sharing, collaboration, while being user-centered. Web 2.0 was adopted by healthcare participants to utilize the core concepts of openness, social networking, participation, collaboration, and apomediation. Apomediation refers to cutting out any middlemen or "gatekeepers" when accessing Internet information and going directly to the information, which is vetted by experts.
"One major concern of healthcare professionals regarding the use of social media in healthcare is that, by nature, it is open and the information is not ‘controllable,’” according to Jeff Cain, EdD, MS, director of education technology at the University of Kentucky College of Pharmacy, Lexington, Ky., who spoke on this topic at the 22nd annual meeting of the Academy of Managed Care Pharmacy in San Diego.
"Many healthcare professionals also use micro-blogging applications such as Twitter to disseminate and receive health-related information and research. By following other healthcare Twitterers, one can quickly be introduced to new publications, stories, and online articles of interest that she or he may not have discovered without extensive searching," said Dr Cain.
Examples of healthcare community sharing sites are PatientsLikeMe, HelloHealth, and Google Health. PatientsLikeMe is a site for patients with similar disease states. Currently there are more than 60,000 users for 19 conditions. Patients communicate about treatments, side effects, and other topics. Patient information is de-identified and aggregated, and can be purchased by pharmaceutical companies and health plans, to be used for research and marketing purposes.
“From the patient perspective, social media has permitted the unprecedented ability for users to socially connect with others who suffer from the same affliction or disease state,” according to Dr Cain. “For those with rare diseases, social networking capabilities of some of the patient community sites allow patients to locate, communicate with, encourage, and support others with similar problems.”
PSG: Specialty Drug Trend Continues Upward
Higher costs per claim, coupled with an increased number of patients using specialty drugs, has contributed to higher spend.
Read More
FDA Approves Oral JAK Inhibitor for Alopecia
Leqselvi is approved to treat adults with severe alopecia. One-third of patients in clinical trials experienced 80% scalp hair coverage at 24 weeks.
Read More
Nonsteroidal Drug for Duchenne Launches with a $700,000 Price Tag
Duvyzat was approved in March 2024 and works to reduce the inflammation and loss of muscle experienced by patients with Duchenne muscular dystrophy.
Read More
FDA Approves Second Biosimilar of Soliris
Epysqli is a monoclonal antibody that is approved to treat two rare conditions that break down red blood cells.
Read More
GoodRx to Offer Boehringer Ingelheim’s Humira Biosimilar
Boehringer Ingelheim’s high- and low-concentration adalimumab-adbm will be available through GoodRx for $550 for two-pack, which represents a 92% discount from the Humira list price.
Read More
FDA Sets Review Date for Cell Therapy for Post-Transplant Complication
If approved, tabelecleucel would be the first therapy specifically to treat Epstein-Barr virus related post-transplant lymphoproliferative disease. The FDA’s action date is Jan. 15, 2025.
Read More
PSG: Specialty Drug Trend Continues Upward
Higher costs per claim, coupled with an increased number of patients using specialty drugs, has contributed to higher spend.
Read More
FDA Approves Oral JAK Inhibitor for Alopecia
Leqselvi is approved to treat adults with severe alopecia. One-third of patients in clinical trials experienced 80% scalp hair coverage at 24 weeks.
Read More
Nonsteroidal Drug for Duchenne Launches with a $700,000 Price Tag
Duvyzat was approved in March 2024 and works to reduce the inflammation and loss of muscle experienced by patients with Duchenne muscular dystrophy.
Read More
FDA Approves Second Biosimilar of Soliris
Epysqli is a monoclonal antibody that is approved to treat two rare conditions that break down red blood cells.
Read More
GoodRx to Offer Boehringer Ingelheim’s Humira Biosimilar
Boehringer Ingelheim’s high- and low-concentration adalimumab-adbm will be available through GoodRx for $550 for two-pack, which represents a 92% discount from the Humira list price.
Read More
FDA Sets Review Date for Cell Therapy for Post-Transplant Complication
If approved, tabelecleucel would be the first therapy specifically to treat Epstein-Barr virus related post-transplant lymphoproliferative disease. The FDA’s action date is Jan. 15, 2025.
Read More